NCT00287092View on ClinicalTrials.gov

Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule in Infants

PHASE3CompletedINTERVENTIONAL

Enrollment

807

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

May 31, 2007

Study Completion Date

September 30, 2008

Conditions

PertussisDiphtheriaTetanusPoliomyelitisHaemophilus Influenzae Type b

Interventions

BIOLOGICAL

DT5aP-IPV-Hib 5-component Pertussis vaccine

0.5 mL, IM

BIOLOGICAL

Infanrix® -IPV+Hib

0.5 mL, IM

Trial Locations (14)

15140

Lahti

20520

Turku

28120

Pori

33520

Tampere

40100

Jyväskylä

48100

Kotka

90100

Oulu

02100

Espoo

00100

Helsinki

00930

Helsinki

04400

Järvenpää

01300

Vantaa

01600

Vantaa

S-831 83

Östersund

All Listed Sponsors

lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT00287092 - Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule in Infants | Biotech Hunter | Biotech Hunter